ACTRIMS 2022 | Tailoring treatment in MS with new S1P receptor modulators

Jiwon Oh, MD, PhD, St. Michael’s Hospital, University of Toronto, Toronto, Canada, comments on the growing availability of Sphingosine 1-phosphate (S1P) receptor modulators for the treatment of multiple sclerosis (MS). Siponimod, ozanimod, and ponesimod have all been approved in recent years and are more selective than older S1P receptor modulators. Dr Oh notes that an expanding treatment armamentarium allows individual patients to be treated with agents more tailored to their needs. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.